| Model Number |
164275 |
| Medical Device Problem Code |
Noise, Audible (3273)
|
| Health Effect - Clinical Code |
No Clinical Signs, Symptoms or Conditions (4582)
|
| Date of Event |
09/22/2022
|
|
Type of Reportable Event
|
Malfunction
|
|
Additional Manufacturer Narrative
|
|
Terumo has not received the device for evaluation; therefore, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.(b)(4).
|
| |
|
Event or Problem Description
|
|
The user facility reported to terumo cardiovascular that during cardiopulmonary bypass, the pump head was making a high-pitched sound during recirculation.Per facility, the pumphead continued to squeal once in contact with blood.No known impact or consequence to patient.The product was not changed out.The surgery was completed successfully.
|
| |
|
Additional Manufacturer Narrative
|
|
Type of investigation #1: 10 - testing of actual/suspected device.Type of investigation #2: 3331 - analysis of production records.Investigation finding: 213 - no device problem found.Investigation conclusions: 22 - known inherent risk of device.The affected sample was inspected upon receipt to show no visual anomalies.The sample was built into a saline circuit and set up on a sarns drive motor.The rpm was set at 900 and ramped up by 300 rpm every ten minutes for one hour for a maximum of 2400 rpm.During each interval, the sample was observed for any running sound anomalies.No sound anomalies or abnormalities with the functionality were observed during the test.The noise was not able to be replicated on the complaint sample; however, the issue experienced by the customer is likely due to an abnormal interaction between the seal rotor and stator surfaces.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
| |
|
Additional Manufacturer Narrative
|
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on october 13, 2022.H3 (device evaluation anticipated by manufacturer - a second follow-up will be submitted upon completion of the investigation and/or submission of new information, thus tcvs references conclusions code (b)(4).All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
| |
|
Search Alerts/Recalls
|